Top execs bicker over Sanofi’s plan to unload $8B portfolio of old drugs

Arlene Weintraub

Back in April, Sanofi CEO Chris Viehbacher said he planned to sell off some of the company's mature products to make room for higher-value "bolt-on" acquisitions. Rumors about potential buyers immediately started flying. Analysts estimated the could fetch $ 8 billion or more.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS